바이오테크 보도자료
-
- PMC Group International Announces Acquisition of Copperhead Chemical Company
- PMC Group International, Inc., which is an independent arm of PMC Group Companies, announced the acquisition of Cobra Investments Management Inc. and its two subsidiaries, Copperhead Chemical Company Inc. (“...
- 2021년 02월 23일
-
- Sky Labs Provided CART-I For Clinical Study of Oxford University Professor Betts
- Sky Labs, a healthcare start-up, announced that CART-I, its ring-type heart-monitoring device, had been provided for Timothy Betts, professor of medicine at Oxford University, for his clinical research. Prof...
- 2021년 02월 23일
-
- LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
- LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US. LG Chem licensed LG00303174 (TT-01025) from T...
- 2021년 02월 23일
-
- Laipac Technology Partners With Two UAE Companies to Launch World’s First AI Rapid Antigen Test System
- Laipac Technology Inc., of Ontario, Canada, an award-winning leader in the development of IoMT (Internet of Medical Things) is pleased to announce their partnership with UAE companies YAS Pharmaceuticals LLC...
- 2021년 02월 22일
-
- Kaneka Eurogentec Receives GMP Accreditation for New mRNA Manufacturing Facility - COVID-19 Vaccine Production Ongoing
- Kaneka Eurogentec: A new GMP facility for active pharmaceutical ingredient production The new facility audited and accredited by Belgian Authorities will allow the production and the purification of up to 10...
- 2021년 02월 17일
-
- Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
- Ferring Pharmaceuticals, Rebiotix Inc., a Ferring Company, and MyBiotics Pharma Ltd. today announced a multi-year strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial...
- 2021년 02월 17일
-
- Thoma Bravo-Owned Quorum Software and Aucerna to Merge and Acquire TietoEVRY's Oil and Gas Software Business
- Quorum Software (“Quorum”), a world leader in digital transformation for the energy industry, today announced two major transactions that will result in the creation of the world's largest software provider ...
- 2021년 02월 16일
-
- Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today at the 2021 Transplantation & Cellular Therapy (TCT) Meetings Digital Experience announced new, late-breaking Phase 3 data from the ...
- 2021년 02월 15일
-
- Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darv...
- 2021년 02월 15일
-
- Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darv...
- 2021년 02월 10일
-
- MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA
- Triastek, Inc. (“Triastek”), a pharmaceutical company specializing in 3D printing of drug products, announced today that the United States Food and Drug Administration (FDA) has approved its Investigational ...
- 2021년 02월 10일
-
- Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL
- Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, today announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics (NA...
- 2021년 02월 10일
전시회
